Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation.

Molecular pharmacology - 1 Mar 2008

Goncharova Elena A, Goncharov Dmitry A, Chisolm Amelia, Spaits Matthew S, Lim Poay N, Cesarone Gregory, Khavin Irene, Tliba Omar, Amrani Yassine, Panettieri Reynold A, Krymskaya Vera P

Abstract excerpt

Lymphangioleiomyomatosis (LAM), a rare pulmonary disorder, manifests as an abnormal neoplastic growth of smooth muscle-like cells within the lungs. Mutational inactivation of tumor suppressor tuberous sclerosis complex 2 (TSC2) in LAM constitutively activates the mammalian target of rapamycin (mT...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Interferon-beta
Share to Leiomyoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Muscle, Smooth

Share to Receptors, Interferon

Share to Ribosomal Protein S6 Kinases, 70-kDa

Share to Sirolimus

Share to Tuberous Sclerosis Complex 2 Protein

Share to Uterine Neoplasms

Source

Identifiers

PMID: 18094073
DOI: 10.1124/mol.107.040824

Genes

TSC2
STAT1
STAT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18094073-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation.PMID 18094073Read ↗

STAT1 Promotes PD-L1 Activation and Tumor Growth in LymphangioleiomyomatosisSemantic proximity Read ↗

Lost in translation: a neglected mTOR target for lymphangioleiomyomatosisSemantic proximity Read ↗

Lymphangioleiomyomatosis: Current understanding and potential treatments.Semantic proximity Read ↗

Combination of Volasertib and Rapamycin Inhibits the Regrowth of TSC2-Deficient TumorsSemantic proximity Read ↗

Modulation of Cell Migration and Invasiveness by Tumor Suppressor TSC2 in LymphangioleiomyomatosisSemantic proximity Read ↗

Tumour suppressors hamartin and tuberin: intracellular signalling.Semantic proximity Read ↗

Extracellular Matrix-Induced Genes May Reduce Response to Rapamycin in LAMSemantic proximity Read ↗

mTOR dysregulation induces IL6 and paracrine AT2 cell senescence impeding lung repair in lymphangioleiomyomatosisSemantic proximity Read ↗

[Current understanding and perspectives of lymphangioleiomyomatosis].Semantic proximity Read ↗

Integration of mTOR and estrogen–ERK2 signaling in lymphangioleiomyomatosis pathogenesisSemantic proximity Read ↗

Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis.Semantic proximity Read ↗

MicroRNA-21 is Induced by Rapamycin in a Model of Tuberous Sclerosis (TSC) and Lymphangioleiomyomatosis (LAM)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.